Augmented Reality (AR) neurorehabilitation platform, Stroll, has entered the US market in a $3 million collaboration with Cleveland Clinic.
According to the parties, the agreement will see Cleveland Clinic gain an exclusive software license and become a shareholder in Strolll.
Cleveland Clinic’s digital therapeutic software module, Dual-task Augmented Reality Treatment (DART), will be integrated into Strolll’s platform. DART has been designed to help Parkinson’s patients, including the management of postural instability and gait dysfunction.
In a statement, Jay Alberts, PhD, Vice Chair of Innovation in Cleveland Clinic’s Neurological Institute commented: “To our knowledge, DART is the first digital therapeutic software for Parkinson’s disease that has undergone rigorous evaluation against an accepted intervention in a randomized controlled trial.
“These findings suggest that we can address barriers to wider use of dual-task training. The next step is to extend this into the patient’s home.
“We have an aligned vision for the future of digital therapeutics in neuro-rehab and we’re looking forward to supporting Strolll through this new collaboration.”
The parties have confirmed that, as part of the agreement Strolll will establish its US head office on Cleveland Clinic’s main campus.
